Trials / Withdrawn
WithdrawnNCT00214214
A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- —
Summary
The rationale for the study is to determine if Campath-1H can be used in patients recently diagnosed with type I DM, to induce a state of immunological unresponsiveness such that subjects can safely preserve beta cell mass and eliminate or lower insulin requirements, preserving excellent metabolic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Campath 1H® (Alemtuzumab) |
Timeline
- Start date
- 2005-10-01
- First posted
- 2005-09-21
- Last updated
- 2015-10-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00214214. Inclusion in this directory is not an endorsement.